These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 25216185)

  • 1. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
    Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
    Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
    Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
    Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
    Lee JH; Park KS; Alberobello AT; Kallakury B; Weng MT; Wang Y; Giaccone G
    Clin Cancer Res; 2013 Dec; 19(24):6777-86. PubMed ID: 24158701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesicle-associated membrane protein 8 knockdown exerts anti-proliferative, pro-apoptotic, anti-autophagic, and pro-ferroptotic effects on colorectal cancer cells by inhibition of the JAK/STAT3 pathway.
    Xu Y; Yang T; Xu Q; Tang Y; Yang Q
    J Bioenerg Biomembr; 2024 Aug; 56(4):419-431. PubMed ID: 38720136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V-set and immunoglobulin domain containing 4 inhibits oxidative stress, mitochondrial dysfunction, and inflammation to attenuate Parkinson's disease progression by activating the JAK2/STAT3 pathway.
    Cai P; Wang J; Xu J; Zhang M; Yin X; He S; Zhuang J
    J Neuroimmunol; 2024 Jun; 391():578345. PubMed ID: 38759519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
    Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
    J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcuminoids Modulated the IL-6/JAK/STAT3 Signaling Pathway in LoVo and HT-29 Colorectal Cancer Cells.
    Li Q; Ding Y; Ou Y; Li M; Jithavech P; Buranasudja V; Sritularak B; Xu Y; Rojsitthisak P; Han J
    Curr Pharm Des; 2023; 29(36):2867-2876. PubMed ID: 37957863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLK3 positively promoted colorectal cancer proliferation by activating IL-6/STAT3 signaling.
    Ma Y; Gao F; Liu Y
    Exp Cell Res; 2024 Jul; 440(1):114132. PubMed ID: 38885806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 serves as a critical factor in various cancer progression and therapy.
    Mohamed AH; Ahmed AT; Al Abdulmonem W; Bokov DO; Shafie A; Al-Hetty HRAK; Hsu CY; Alissa M; Nazir S; Jamali MC; Mudhafar M
    Med Oncol; 2024 Jun; 41(7):182. PubMed ID: 38900329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer.
    Wei N; Burnett J; Crocker DL; Huang Y; Li S; Wipf P; Chu E; Schmitz JC
    Biochem Pharmacol; 2023 Jun; 212():115564. PubMed ID: 37116665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
    Malemud CJ; Blumenthal DE
    World J Orthop; 2014 Sep; 5(4):496-503. PubMed ID: 25232525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
    Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
    Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.
    Menet CJ
    Pharm Pat Anal; 2014 Jul; 3(4):449-66. PubMed ID: 25291316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.
    Liu H; Ren G; Wang T; Chen Y; Gong C; Bai Y; Wang B; Qi H; Shen J; Zhu L; Qian C; Lai M; Shao J
    Carcinogenesis; 2015 Apr; 36(4):459-68. PubMed ID: 25750173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
    Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
    Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in irreversible kinase inhibitors.
    Gilbert AM
    Pharm Pat Anal; 2014 Jul; 3(4):375-86. PubMed ID: 25291312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic development in psoriasis.
    Sobell JM; Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
    Adesoye T; Tripathy D; Hunt KK; Keyomarsi K
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.